Eris Lifesciences Q1 Review - Steady Outperformance Across Major Therapies: Motilal Oswal


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Eris Lifesciences Ltd. delivered an operationally better-than-expected Q1 FY23 performance, led by outperforming the industry in cardio-metabolic, central nervous system, dermatology, and women’s health therapies.

In addition to gaining market share in existing brands, it is on track for introductions across major therapies over the next 12-15 months.

We reduce our FY23/FY24 earnings per share estimate by 8%/2%, factoring in:

  1. increased marketing spends on launches, and

  2. higher employee cost towards the addition of medical representatives in its Insulin portfolio.

We remain positive on Eris’ strategy of scaling up newer therapies and introducing superior products in the base therapies.

Click on the attachment to read the full report:


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.


Image and article originally from Read the original article here.